1. Inicio
  2. Publicaciones
  3. Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217

Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pedrosa, N
  • Vico, H

Grupos

Abstract

Nowadays, there is an unmet need for reliable and minimally-invasive diagnosis tools capable of detecting Alzheimer's disease at early stages. Such tools could significantly reduce the reliance on confirmatory tests that are invasive and costly, such as cerebrospinal fluid (CSF) biomarkers and neuroimaging. The aim of this study is to validate previously developed diagnosis tools (multivariate models and plasma p-Tau217 levels) in three independents cohorts. For this, a cohort was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) including some variables (age, Apolipoprotein E (ApoE) genotype, plasma p-Tau217, CSF biomarkers) (n = 113); and two cohorts from cognitive disorders units (Hospital Universitari i Polit & egrave;cnic La Fe (HUiPLaFe, n = 163), Hospital Doctor Peset (n = 31)), whose plasma samples were analysed to determine plasma p-Tau217, and to evaluate the previous diagnosis tools performance. For the cohort from HUiPLaFe, the multivariate model (plasma p-Tau217, age, ApoE genotype) showed a sensitivity of 94.9% and a specificity of 88.2%; for the cohort from Hospital Doctor Peset, the sensitivity was 100% and specificity 80%; for the ADNI cohort, sensitivity was 89.5% and specificity 39.5%. Regarding the plasma p-Tau217 levels, the results were satisfactory for the cognitive disorders units; while ADNI cohort showed very low specificity. In conclusion, the multivariate model was clinically validated in independent cohorts from clinical units, representing its first step for implementation.

© 2025. The Author(s).

Datos de la publicación

ISSN/ISSNe:
2045-2322, 2045-2322

SCIENTIFIC REPORTS  NATURE PUBLISHING GROUP

Tipo:
Article
Páginas:
1472-1472
PubMed:
41354755
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,005 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Alzheimer disease; Plasma; Diagnosis model; Validation; Implementation

Campos de Estudio

Proyectos y Estudios Clínicos

Validación de biomarcadores plasmáticos para la detección temprana y específica de la enfermedad de Alzheimer y evaluación pronóstica a 2 años.

Investigador Principal: MARÍA CONSUELO CHÁFER PERICÁS

CNS2022-135327 . MINISTERIO DE CIENCIA E INNOVACION . 2023

Acción de fortalecimiento institucional transversal para una medicina 5P (AFIT-5P)

Investigador Principal: PILAR NOS MATEU

FORT23/00021 . INSTITUTO DE SALUD CARLOS III . 2024

Compartir